BioSpace News Archive

Business

Basilea Announces Completion of the License Agreement Extension With Pfizer for Antifungal Cresemba for China and Asia Pacific

The amendment was subject to customary regulatory review which has completed. Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections.

January 10, 2018
·
4 min read
Deals

Predictive Technology Group Finalizes Letter of Intent to Acquire FlagshipHealth Group

The deal allows Predictive Technology Group to develop, launch, and grow its services directed at limiting disease and improving the health and well-being of individuals confronting a wide-range of medical conditions.

January 10, 2018
·
5 min read
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2017

Essilor International is the world’s leading ophthalmic optics company.

January 10, 2018
·
1 min read
Stimwave Inks $50M for Launch of Chronic Pain Neuromod Device

The cash will fuel the launch of the world’s first wireless, micro-technology, drug-free neuromodulation device for relief of chronic pain.

January 10, 2018
·
3 min read
Biotech Bay

CureVac Highlights Key 2018 Corporate Milestones and Outlook

CureVac AG today outlined key 2018 milestones in conjunction with its presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.

January 10, 2018
·
5 min read
Drug Development

First Treatment for SAb Biotherapeutics’ MERS Drug Appears Safe in NIH Phase I Clinical Trial

Results of the study were published today in The Lancet Infectious Diseases.

January 10, 2018
·
4 min read
UBI Blockchain Internet Announces Hong Kong Government Financing of Company’s Blockchain-Based Food and Drug Safety Technology Development Project With Hong Kong Polytechnic University

The agreement between UBI and HKSAR for financing the project is fully effective, with total financing about HK$6,000,000.

January 10, 2018
·
3 min read
Policy

BIO Statement on House Energy & Commerce Committee 340B Drug Pricing Program Review

BIO President and CEO Jim Greenwood issued the following statement regarding the review of the 340B drug pricing program released by the House Energy & Commerce Committee today:

January 10, 2018
·
2 min read